Der var en lav, ensartet overordnet forekomst af virologisk svigt (viral load > 50 kopier/ ml) både i én gang daglig og to gange daglig behandlingsgrupperne (henholdsvis 10% og 8%).
There was a low, similar overall incidence of virologic failure (viral load > 50 copies/ ml) in both the once and twice daily treatment groups (10% and 8% respectively).